Discovery of novel phenyl triazole analogs as TRK/ALK dual inhibitors with prospective antitumor effects

The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer

Luc Friboulet, Nanxin Li, Ryohei Katayama et al. · Cancer Discovery · 2014 · 842 citations · Full text

Medicine, Oncology, Pharmacology +15

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)

Alexander Drilon, Salvatore Siena, Sai‐Hong Ignatius Ou et al. · Cancer Discovery · 2017 · 817 citations · Full text

Medicine, Oncology, Pharmacology +16

A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion–Positive Solid Tumors

Alexander Drilon, Ramamoorthy Nagasubramanian, James F. Blake et al. · Cancer Discovery · 2017 · 433 citations · Full text

Medicine, Oncology, Pharmacology +16

Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications

Elena Ardini, Maria Menichincheri, Patrizia Banfi et al. · Molecular Cancer Therapeutics · 2016 · 312 citations · Full text

Medicine, Oncology, Pharmacology +17

Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor

Maria Menichincheri, Elena Ardini, Paola Magnaghi et al. · Journal of Medicinal Chemistry · 2016 · 298 citations · Full text

Medicine, Oncology, Pharmacology +17